HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU REACH

This article was originally published in The Rose Sheet

Executive Summary

Registration, Evaluation and Authorisation of Chemicals regulation likely will be considered by the European Parliament for final approval by fall 2006, European Commission reports in release announcing agreement by the European Council. "The formal Common Position of the Council should be approved under the Austrian Presidency in May 2006, a step that will pave the way for the second reading of the proposal by the European Parliament," commission notes. Parliament approved first reading of the proposal last month. REACH, which will replace 40 existing regs, requires manufacturers or importers of more than one ton per year of a chemical substance to register with a future European Chemicals Agency and provide safety data. Commission "expects entry into force of the Regulation for spring 2007," release states, adding "thereafter it will take about a year for the REACH Agency to be operational"...

You may also be interested in...



REACH Report Suggests Larger Role For Downstream Users

Downstream users may need to be more involved in the registration portion of the European Union REACH chemicals program than previously expected, according to report released Feb. 22

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel